"Morgan Stanley has started covering Ironwood Pharmaceuticals (NASDAQ:IRWD), and its first rating was an “overweight” with a price target of $19.
The primary drug being developed, which will determine much of its near term performance is linaclotide, which targets irritable bowel syndrome with constipation and chronic constipation.
Morgan analysts Sara Slifka and Steven Harr said they see a good chance of passing regulatory hurdles and being a clinical success. If the drug is released in a timely manner it could become the first to relieve pain in this particular health sector.
The two expect losses at the company in 2010 of $0.57 a share, and a $0.47 cents a share loss in 2011."